Skip Navigation LinksHome > January 01, 2012 - Volume 37 - Issue 1 > Giant Cell Tumor of the Mobile Spine: A Review of 49 Cases
Spine:
doi: 10.1097/BRS.0b013e3182233ccd
Clinical Case Series

Giant Cell Tumor of the Mobile Spine: A Review of 49 Cases

Boriani, Stefano MD*; Bandiera, Stefano MD*; Casadei, Roberto MD; Boriani, Luca MD; Donthineni, Rakesh MD, MBA; Gasbarrini, Alessandro MD*; Pignotti, Elettra MSc§; Biagini, Roberto MD; Schwab, Joseph H. MD, MS

Collapse Box

Abstract

Study Design. This is a retrospective review of 49 cases of giant cell tumor (GCT) of the mobile spine treated surgically.

Objective. Our goal was to determine which factors influenced local recurrence.

Summary of Background Data. GCT is a benign, locally aggressive tumor that rarely occurs in the spine. The management of local recurrence can be challenging.

Methods. We performed a retrospective analysis of GCTs of the mobile spine managed between 1970 and 2005. Median follow-up was 145 months with a minimum of 2 years or until death. We used the Kaplan-Meier method to test whether Enneking stage, surgery type, and surgical margin had statistically significant impact on local recurrence. The log rank test was used for comparison, and a P value of less than 0.05 was deemed significant.

Results. Of the 49 patients, 11 (22%) local recurrences occurred. The latest recurrence occurred at 60 months. Age less than 25 years was associated with a worse relapse-free survival (P = 0.03). En bloc resection was associated with better local control with Enneking stage III tumors (P = 0.01); however, intralesional resection provided adequate control of Enneking stage II tumors. There were 6 (12%) cases of metastasis, and 2 patients died from the progression of their disease. One patient died from the complications of the surgery.

Conclusion. En bloc resection should be considered for Enneking stage III GCTs of the mobile spine. The choice of en bloc resection must be balanced with the inherent risks of the procedure. Intralesional resection of Enneking stage II tumors provides adequate local control. Patients should be followed for at least 5 years because local relapse can occur late.

© 2012 Lippincott Williams & Wilkins, Inc.

Follow Us!

  

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.